JP2024530325A5 - - Google Patents

Info

Publication number
JP2024530325A5
JP2024530325A5 JP2024513383A JP2024513383A JP2024530325A5 JP 2024530325 A5 JP2024530325 A5 JP 2024530325A5 JP 2024513383 A JP2024513383 A JP 2024513383A JP 2024513383 A JP2024513383 A JP 2024513383A JP 2024530325 A5 JP2024530325 A5 JP 2024530325A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530325A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/115536 external-priority patent/WO2023030258A1/en
Publication of JP2024530325A publication Critical patent/JP2024530325A/ja
Publication of JP2024530325A5 publication Critical patent/JP2024530325A5/ja
Pending legal-status Critical Current

Links

JP2024513383A 2021-08-31 2022-08-29 抗4-1bbナノボディ Pending JP2024530325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/115621 2021-08-31
CN2021115621 2021-08-31
PCT/CN2022/115536 WO2023030258A1 (en) 2021-08-31 2022-08-29 Anti-4-1bb nanobodies

Publications (2)

Publication Number Publication Date
JP2024530325A JP2024530325A (ja) 2024-08-16
JP2024530325A5 true JP2024530325A5 (cg-RX-API-DMAC7.html) 2025-09-08

Family

ID=85410851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513383A Pending JP2024530325A (ja) 2021-08-31 2022-08-29 抗4-1bbナノボディ

Country Status (10)

Country Link
US (2) US20240383993A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396234A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024530325A (cg-RX-API-DMAC7.html)
KR (1) KR20240049829A (cg-RX-API-DMAC7.html)
CN (1) CN118176211A (cg-RX-API-DMAC7.html)
AU (1) AU2022336889A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230481A1 (cg-RX-API-DMAC7.html)
IL (1) IL311144A (cg-RX-API-DMAC7.html)
MX (1) MX2024002720A (cg-RX-API-DMAC7.html)
WO (1) WO2023030258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530325A (ja) 2021-08-31 2024-08-16 ラノバ メディシンズ リミテッド 抗4-1bbナノボディ
AU2024229974A1 (en) * 2023-02-28 2025-09-11 LaNova Medicines Limited Ceacam5-dependent 4-1bb-agonistic bispecific antibodies
WO2025214249A1 (en) * 2024-04-12 2025-10-16 Suzhou Biomissile Pharmaceuticals Co., Ltd. Anti-4-bb single domain antibodies, bispecific antibodies and uses thereof
WO2026075820A1 (en) * 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CN104829730A (zh) 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
CA3082297A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
TW201932491A (zh) * 2018-01-22 2019-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗4-1bb抗體、其抗原結合片段及其醫藥用途
CN108659131B (zh) 2018-05-28 2021-09-14 长春力太生物技术有限公司 一种抗ceacam-5的单域抗体及其应用
TW202035447A (zh) * 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
CN112646031B (zh) * 2019-10-10 2021-12-07 天境生物科技(上海)有限公司 抗4-1bb纳米抗体及其用途
CN117355540A (zh) 2021-05-21 2024-01-05 百济神州有限公司 抗cd137抗体和使用方法
JP2024530325A (ja) 2021-08-31 2024-08-16 ラノバ メディシンズ リミテッド 抗4-1bbナノボディ

Similar Documents

Publication Publication Date Title
JP7323513B2 (ja) 抗4-1bb抗体とその作製及び使用方法
JP2023526774A5 (cg-RX-API-DMAC7.html)
TWI489996B (zh) Cd127結合蛋白質
JP4294596B2 (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2022512653A5 (cg-RX-API-DMAC7.html)
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
JP2021534762A5 (cg-RX-API-DMAC7.html)
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
JP2023506184A5 (cg-RX-API-DMAC7.html)
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2018527919A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2023549851A5 (cg-RX-API-DMAC7.html)
JP2020516309A5 (cg-RX-API-DMAC7.html)
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2017537082A5 (cg-RX-API-DMAC7.html)
JP2024532489A5 (cg-RX-API-DMAC7.html)
JP2023511898A5 (cg-RX-API-DMAC7.html)
JPWO2021241616A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)
JP2022512646A5 (cg-RX-API-DMAC7.html)